Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell carcinoma and has shown clinical activity as monother...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology Jg. 22; H. 6; S. 848 - 857
Hauptverfasser:	Stratigos, Alexander J, Sekulic, Aleksandar, Peris, Ketty, Bechter, Oliver, Prey, Sorilla, Kaatz, Martin, Lewis, Karl D, Basset-Seguin, Nicole, Chang, Anne Lynn S, Dalle, Stèphane, Orland, Almudena Fernandez, Licitra, Lisa, Robert, Caroline, Ulrich, Claas, Hauschild, Axel, Migden, Michael R, Dummer, Reinhard, Li, Siyu, Yoo, Suk-Young, Mohan, Kosalai, Coates, Ebony, Jankovic, Vladimir, Fiaschi, Nathalie, Okoye, Emmanuel, Bassukas, Ioannis D, Loquai, Carmen, De Giorgi, Vincenzo, Eroglu, Zeynep, Gutzmer, Ralf, Ulrich, Jens, Puig, Susana, Seebach, Frank, Thurston, Gavin, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Bowler, Timothy, Fury, Matthew G
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.06.2021 Elsevier Limited Elsevier
Schlagworte:	Adverse events Basal cell carcinoma Cancer Colitis FDA approval Hematology, Oncology, and Palliative Medicine Immunotherapy Intolerance Life Sciences Lung cancer Metastases Metastasis Monoclonal antibodies Non-small cell lung carcinoma Patients PD-1 protein Photography Radiation therapy Radiology Skin cancer Squamous cell carcinoma Statistical analysis Surgery Targeted cancer therapy Toxicity Tumors United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!